Compare · ARVN vs GLUE
ARVN vs GLUE
Side-by-side comparison of Arvinas Inc. (ARVN) and Monte Rosa Therapeutics Inc. (GLUE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. ARVN focuses on Biotechnology: Pharmaceutical Preparations, while GLUE focuses on Biotechnology: Biological Products (No Diagnostic Substances).
- GLUE is the larger of the two at $738.3M, about 1.7x ARVN ($423.0M).
- GLUE has been more active in the news (10 items in the past 4 weeks vs 9 for ARVN).
- ARVN has more recent analyst coverage (25 ratings vs 12 for GLUE).
- Company
- Arvinas Inc.
- Monte Rosa Therapeutics Inc.
- Price
- -
- -
- Market cap
- $423.0M
- $738.3M
- 1M return
- -
- -22.16%
- 1Y return
- -
- -45.20%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2018
- 2021
- News (4w)
- 9
- 10
- Recent ratings
- 25
- 12
Arvinas Inc.
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Bayer AG, and Insilico Medicine, Inc. Arvinas, Inc. was incorporated in 2013 and is based in New Haven, Connecticut.
Latest ARVN
- GeneDx Announces Leadership Transition
- SEC Form EFFECT filed by Arvinas Inc.
- Arvinas to Present at Jefferies Global Healthcare Conference
- VP, Chief Accounting Officer Loomis David K sold $1,475 worth of shares (232 units at $6.36), decreasing direct ownership by 0.58% to 39,961 units (SEC Form 4) (withholding tax)
- Arvinas to Present Preliminary Clinical Data from Early Monotherapy Dose Escalation Cohorts in the Phase 1 Trial for ARV-393 (Zaloblideg), a PROTAC BCL6 Degrader, at the 2026 American Society of Hematology (ASH®) Annual Meeting
- SEC Form S-3 filed by Arvinas Inc.
- SEC Form 10-Q filed by Arvinas Inc.
- Arvinas Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- Arvinas Reports Third Quarter 2026 Financial Results and Provides Corporate Update
- Arvinas Announces Return of Early Career Researcher Award to Recognize Innovation in Targeted Protein Degradation
Latest GLUE
- Amendment: SEC Form SCHEDULE 13G/A filed by Monte Rosa Therapeutics Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Monte Rosa Therapeutics Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Monte Rosa Therapeutics Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Monte Rosa Therapeutics Inc.
- Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2026 on the Potential of MRT-8102 in Gout
- SEC Form 10-Q filed by Monte Rosa Therapeutics Inc.
- Monte Rosa Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Monte Rosa Therapeutics Announces Third Quarter 2026 Financial Results and Business Updates
- Monte Rosa Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences